Hyoscine butylbromide
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06207539 | Dec 2022 → Mar 2023 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 13 trials · 1 missed | ||||||
| Phase 1 | NCT01734902 | Nov → Dec 2012 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT00646061 | Nov 2007 → Dec 2008 | urinary system disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02261077 | May → Jul 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04823065 | Sep 2018 → Aug 2023 | endometrial cancer, ovarian cancer | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02242292 | Apr 2006 → Jan 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00409890 | Jun → Oct 2005 | — | University Hospital of the West Indies | Completed | No outcome recorded |
| Phase 2 | NCT02229786 | Feb 1998 → Oct 1999 | digestive system disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 35 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT03961165 | May 2019 → Aug 2021 | obstetric disorder | Oslo University Hospital | Completed | Missed primary |
| Phase 3 | NCT02582307 | Mar 2017 → Dec 2018 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Missed primary |
| Phase 3 | NCT01929044 | Aug 2013 → Feb 2015 | intestinal disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT02242305 | Nov 2008 → Jul 2009 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 3 | NCT00740324 | Aug 2008 → Mar 2009 | — | Nihon Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06927817 | Nov 2020 → Nov 2021 | cholecystitis | University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02709603 | Mar → May 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT01609855 | Jan → Jun 2012 | colon adenoma | Valduce Hospital | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07271303 | Feb → Dec 2026 expected | — | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07814976 | Jan 2026 → Jan 2027 expected | choledocholithiasis | Riga East Clinical University Hospital | Recruiting | No outcome recorded |
| — | NCT07383571 | Oct 2025 → Apr 2026 | — | Cairo University | Completed | No outcome recorded |
| — | NCT03441217 | Jul → Aug 2019 | — | Saint Thomas Hospital, Panama | Completed | No outcome recorded |
| — | NCT03513250 | May 2018 → Jul 2020 | interstitial cystitis | Cairo University | Completed | No outcome recorded |
| — | NCT03499743 | Apr → Sep 2018 | — | Cairo University | Completed | No outcome recorded |
| — | NCT02725398 | Dec 2013 → Dec 2016 | — | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 2 | NCT02710305 Comparator | Apr → Nov 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02839213 Comparator | Oct 2015 → May 2016 | — | Woman's Health University Hospital, Egypt | Completed | No outcome recorded |
| Phase 2 | NCT00932737 Comparator | Jun 2009 → Feb 2010 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/3 | NCT02714699 Comparator | Oct 2016 → Mar 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT05719467 Comparator | Jan 2023 → Jan 2025 overdue | pregnancy disorder | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT01854073 Comparator | Feb 2014 → Apr 2017 | dystocia | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT00731198 Comparator | Aug 2008 → Mar 2009 | bile duct disorder, pancreas disorder | Changhai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04785118 Comparator | Oct 2021 → Dec 2022 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT04682860 Comparator | Sep → Dec 2021 | gastroenteritis | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 4 | NCT04349722 Comparator | Dec 2019 → Jun 2020 | — | National University of Malaysia | Completed | No outcome recorded |
| Phase 4 | NCT04069078 Comparator | Oct 2019 → Feb 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT03055390 Comparator | Feb 2017 → Jan 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02009306 Background | Jan 2017 → Feb 2018 | — | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02714231 Comparator | Mar 2016 → Feb 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT02824679 Comparator | Jul 2015 → Dec 2016 | — | Ahmed M Maged, MD | Completed | No outcome recorded |
| Phase 4 | NCT02508142 Comparator | Jul 2015 → Aug 2016 | Cramp-fasciculation syndrome | Kocaeli University | Unknown | No outcome recorded |
| Phase 4 | NCT02098889 Comparator | May → Nov 2012 | — | Sisli Hamidiye Etfal Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01281501 Background | Jan → Oct 2011 | dyspepsia | Chulalongkorn University | Completed | Missed primary |
| — | NCT06056869 Comparator | Sep 2023 → Apr 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| — | NCT07474350 Comparator | Sep 2023 → Jan 2024 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT05911126 Comparator | Jun → Oct 2023 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04751084 Comparator | May 2020 → Apr 2024 | — | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT03359655 Comparator | Jun → Dec 2018 | — | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT03430362 Comparator | Mar 2018 → Dec 2019 | dystocia | Cairo University | Completed | No outcome recorded |
| — | NCT03226145 Comparator | Jul 2017 → Sep 2020 | constipation disorder, irritable bowel syndrome | University of Nottingham | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyoscine Butyl-bromide | “The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's...” NCT00932737 ↗33“We hypothesized that prophylactic use of hyoscine butyl-bromide (HBB) could improve hemodynamics and reduce IONV in parturients undergoing cesarean section.” PMID 35448942 ↗ Apr 2022 “A randomized controlled study of the effect of hyoscine butylbromide on duration of labor in primigravida women with prolonged labor.” PMID 33983512 ↗ May 2021 “Hyoscine butylbromide belongs to the parasympatholytic group of drugs and is a semisynthetic derivative of scopolamine.” NCT02839213 ↗ “Hyoscine Butyl-bromide, also known as scopolamine butyl-bromide and sold under the brand name Buscopan.9” NCT04785118 ↗ “* Glycopyrronium * Hyoscine butylbromide” NCT02009306 ↗ |
| Known as | buscopan | “one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.” NCT03513250 ↗11“intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion” NCT03499743 ↗ “Hyoscine butyl bromide (in the form of Buscopan®) is effective in hastening cervical effacement and dilatation” NCT00409890 ↗ “Hyoscine Butyl-bromide, also known as scopolamine butyl-bromide and sold under the brand name Buscopan.9” NCT04785118 ↗ “Drug: hyoscine butyl bromide (buscopan)” NCT02714231 ↗ “Hyoscine-N-butylbromide (HBB, Buscopan)” NCT04349722 ↗ “Buscopan® (hyoscine butylbromide)” NCT01929044 ↗ |
| Known as | Buscopan: Hyoscine Butyl Bromide 20mg/2 ml i.v. | “Buscopan: Hyoscine Butyl Bromide 20mg/2 ml i.v.” NCT01609855 ↗ |
| Known as | Butylscopolamine Bromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03961165 ↗ |
| Known as | HBB | “The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's...” NCT00932737 ↗6“We hypothesized that prophylactic use of hyoscine butyl-bromide (HBB) could improve hemodynamics and reduce IONV in parturients undergoing cesarean section.” PMID 35448942 ↗ Apr 2022 “However, Hyoscine butyl bromide (HBB) has a quaternary ammonium structure that does not cross through the blood-brain barrier” NCT04785118 ↗ “OBJECTIVE: To assess the safety and efficacy of hyoscine butyl bromide (HBB) in primipara with prolonged 1st stage of labor.” PMID 33983512 ↗ May 2021 “Although Hyoscine N butyl bromide (HBB) is used liberally to facilitate cervical dilatation” NCT02098889 ↗ “Hyoscine butylbromide (HBB), trade name: Buscopan, is an anticholinergic agent” NCT02582307 ↗ “Hyoscine-N-butyl bromide (HBB), placebo tablet” NCT05911126 ↗ |
| Known as | Hyoscine N-butyl bromide | “Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis” NCT04682860 ↗13“Hyoscine N-butyl bromide also known as scopolamine is a drug with anticholinergic effects” NCT03513250 ↗ “1ml(20mg) of Hyoscine-N-Butylbromide (HBB) (MOLIT ampule,Adeko, Turkey)” NCT02098889 ↗ |
| Known as | scopolamine | “Hyoscine N-butyl bromide also known as scopolamine is a drug with anticholinergic effects” NCT03513250 ↗ |
| Known as | scopolamine butyl-bromide | “Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men” NCT00740324 ↗1“Hyoscine Butyl-bromide, also known as scopolamine butyl-bromide and sold under the brand name Buscopan.9” NCT04785118 ↗ |
| Action | Inhibit | “competitive antagonism to acetyl choline” NCT01854073 ↗ |
| Route | Intravenous | “was administered intravenously 15 minutes before ERCP.” NCT00731198 ↗ |